<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03344172</url>
  </required_header>
  <id_info>
    <org_study_id>HCC# 17-134</org_study_id>
    <secondary_id>R01CA181450</secondary_id>
    <nct_id>NCT03344172</nct_id>
  </id_info>
  <brief_title>Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer</brief_title>
  <acronym>17-134</acronym>
  <official_title>Randomized Phase II Trial of Pre-Operative Gemcitabine, Nab-Paclitaxel, and Hydroxychloroquine With or Without Avelumab (PGHA vs. PGH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nathan Bahary, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized phase II trial that will examine the ability of Avelumab to improve the
      clinical activity of a pre-operative regimen of gemcitabine, nab-paclitaxel and
      hydroxychloroquine in subjects with potentially resectable adenocarcinoma of the pancreas.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 13, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of grade IIb or higher histolopathologic response</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Number of grade IIb+lll+lllm+IV+lVm responses / total number of all grade histolopathologic responses. Histoligic appearance will be assess per the Grading System for Pathological Response: Grade I - Characteristic cytologic changes of malignancy present, but little (&lt; 10%) or no tumor cell destruction is evident; Grade II - Characteristic cytologic changes of malignancy; 10% to 90% of tumor cells are destroyed; Grade IIa - Destruction of 10% to 50% of tumor cells; Grade IIb - Destruction of 51% to 90% of tumor cells; Grade III - Few (&lt; 10%) viable-appearing tumor cells are present; Grade IIIm - Sizable pools of mucin present; Grade IV - No viable tumor cells present; Grade IVm - Acellular pools of mucin present.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CA19-9 response to preoperative chemotherapy compared with the control Gemcitabine/ Abraxane and hydroxychloroquine</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Preoperative and postoperative levels (values) of CA19-9 in tissues will be determined. The change in CA19-9 levels (values) will be compared between treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autophagy biomarker levels by (histo)pathological response</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Autophagy biomarker levels in blood by (histo)pathological response (per the Grading System for Pathological Response), by treatment arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Coagulation Index (CI) (or overall assessment of coagulability)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Comparison of the preoperative and postoperative Thromboelastogram (TEG) Coagulation Index (CI), between treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory biomarkers levels by (histo)pathological response</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Inflammatory biomarkers levels in blood by (histo)pathological response (per the Grading System for Pathological Response), by treatment arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CA19-9 levels by final (histo)pathological response</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Change in CA19-9 levels in blood by (histo)pathological response (per the Grading System for Pathological Response), by treatment arm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pancreatic Cancer Resectable</condition>
  <arm_group>
    <arm_group_label>PGHA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine and Avelumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PGH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine, Nab-Paclitaxel, hydroxychloroquine and Avelumab</intervention_name>
    <description>2 cycles of gemcitabine and nab-paclitaxel (1000mg/m2 &amp; 125mg/m2 - day 1, 8, 15) and hydroxychloroquine (1200mg/day) with Avelumab (days 1 and 15 of each 28-day cycle)</description>
    <arm_group_label>PGHA</arm_group_label>
    <other_name>PGHA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine</intervention_name>
    <description>2 cycles of gemcitabine and nab-paclitaxel (1000mg/m2 &amp; 125mg/m2 - day 1, 8, 15) and hydroxychloroquine (1200mg/day)</description>
    <arm_group_label>PGH</arm_group_label>
    <other_name>PGH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has biopsy-proven adenocarcinoma of the pancreas that is determined to be potentially
             or borderline resectable by National Comprehensive Cancer Network (NCCN) criteria.

          -  Karnofsky performance status of 70-100%.

          -  No active second malignancy with the exception of basal or squamous cell carcinoma of
             the skin.

          -  Has adequate biological parameters as demonstrated by blood counts at screening
             (obtained â‰¤14 days prior to randomization).

          -  Has adequate blood chemistry levels at Baseline visit. -Age &gt;18 years.

          -  Must be able to swallow enteral medications with no requirement for a feeding tube.

        Exclusion Criteria:

          -  Deemed surgically unresectable or unwilling to undergo surgical resection.

          -  Prior use of chemotherapy, radiotherapy, and / or investigational agents for
             pancreatic cancer.

          -  Any evidence of metastasis to distant organs (liver, lung, peritoneum).

          -  Symptomatic evidence of gastric outlet obstruction.

          -  Inability to adhere to study and/or follow-up procedures.

          -  History of allergic reactions or hypersensitivity to the study drugs.

          -  Known or suspected HIV infection Active or history of autoimmune disease or immune
             deficiency.

          -  Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with
             dermatologic manifestations.

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis
             obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of
             active pneumonitis on screening chest computed tomography scan.

          -  Patient with a history of interstitial lung disease, history of slowly progressive
             dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis
             or pulmonary hypersensitivity pneumonitis.

          -  Active hepatitis B virus (HBV) infection (chronic or acute), defined as having a
             positive hepatitis B surface antigen (HBsAg) test at screening.

          -  Known clinically significant liver disease Active tuberculosis Severe infection within
             4 weeks prior to initiation of study treatment Significant cardiovascular disease
             Grade &gt;/= 3 hemorrhage or bleeding event within 28 days prior to initiation of study
             treatment.

          -  Prior allogeneic stem cell or organ transplantation including corneal transplant

          -  Major surgical procedure other than for diagnosis within 4 weeks prior to initiation
             of study treatment.

          -  Any other disease, metabolic dysfunction, physical examination finding, or clinical
             laboratory finding that contraindicates the use of an investigational drug.

          -  Pregnant or breastfeeding, or intending to become pregnant during the study

          -  Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study
             treatment.

          -  History of severe allergic anaphylactic reactions to chimeric or humanized antibodies
             or fusion proteins Known hypersensitivity to Chinese hamster ovary cell products or
             recombinant human antibodies Known allergy or hypersensitivity to any of the study
             drugs or any of their excipients.

          -  Treatment with systemic immunosuppressive medication Patients requiring the use of
             enzyme-inducing anti-epileptic medication Patients with previously documented macular
             degeneration or diabetic retinopathy are excluded.

          -  Subjects with ventricular pacemaker Patients on Coumadin must be willing to switch to
             an alternative subcutaneous Low-molecular-weight heparin (LMWH) or oral agent.

          -  Must not have intractable nausea or vomiting which prohibits the patient from oral
             medications Ability to understand and the willingness to sign a written informed
             consent document.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathan Bahary, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UPMC Hillman Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Summer Drummond, BSN</last_name>
    <phone>4126232677</phone>
    <email>drummondsl@upmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Summer Drummond, BSN, RN, CCRC</last_name>
      <phone>412-623-2677</phone>
      <email>drummondsl@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Barbara Stadterman, MPH, MSCR, CCRP</last_name>
      <phone>412-647-5554</phone>
      <email>stadtermanbm@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nathan Bahary, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Nathan Bahary, MD</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

